Novel Cisplatin-Magnetoliposome Complex Shows Enhanced Antitumor Activity via Hyperthermia

TL;DR

This study introduces a novel magnetoliposome complex loaded with Cisplatin that enhances tumor cell death and improves survival in mice through combined magnetic hyperthermia and chemotherapy.

Contribution

The paper presents a new magnetically responsive nanocarrier that combines chemotherapy and hyperthermia, showing improved efficacy in cancer treatment models.

Findings

ML induces hyperthermia under magnetic fields.

ML enhances apoptosis in tumor cells.

Treatment improves survival in tumor-bearing mice.

Abstract

There are several methods to improve cancer patient survival rates by inducing hyperthermia in tumor tissues, which involves raising their temperature above 41{\deg}C. These methods utilize different energy sources to deliver heat to the target region, including light, microwaves or radiofrequency electromagnetic fields. We have developed a new, magnetically responsive nanocarrier, consisting of liposomes loaded with magnetic nanoparticles and cis-diamminedichloroplatinum (II) (CDDP), commonly known as Cisplatin. The resulting magnetoliposome (ML) is rapidly internalized by lung and pancreas tumor cell lines, stored in intracellular vesicles, and capable of inducing hyperthermia under magnetic fields. The ML has no significant toxicity both in vitro and in vivo and, most importantly, enhances cell death by apoptosis after magnetic hyperthermia. Remarkably, mice bearing induced lung tumors, treated with CDDP-loaded nanocarriers and subjected to an applied electromagnetic field, showed an improved survival rate over those treated with either soluble CDDP or hyperthermia alone. Therefore, our approach of magnetic hyperthermia plus CDDP-ML significantly enhances in vitro cell death and in vivo survival of treated animals.